Against the constant reminder that sugar operates in a bear market, and diversification is imperative for sugar companies to cushion them against volatility, very few have tipped their toes in the maturing bioeconomy promising rich rewards in the high-value-low-volume sector. Investment in synthetic biology platforms has been US$9 bln in Q1 and Q2 20211. The four process conversion technologies supporting the biotech sector are biochemical – enzyme-based via fermentation; thermochemical; hybrid of thermochemical and biochemical; and chemical – mediated by a proprietary catalyst. Of these, the biochemical platform continues to maintain ascendancy as the metabolic engineering toolbox makes significant leaps… Login to continue

Login or sign up